Chemotherapy for Metastatic Lung Cancer
Author Information
Author(s): Ikuko Sekine, Yasushi Nishiwaki, Ryuji Kakinuma, Kenji Kubota, Fumihiko Hojo, Toshihiro Matsumoto, Hiroshi Ohmatsu, Koji Goto, Toshihiro Kodama, Keiichi Eguchi, Toshihiro Shinkai, Toshio Tamura, Yoshihiro Ohe, Hiroshi Kunitoh, Kei Yoshimura, Nobuyuki Saijo
Primary Institution: National Cancer Center Hospital, Japan
Hypothesis
Does adding irinotecan to the standard cisplatin and etoposide regimen improve efficacy against advanced lung cancer?
Conclusion
The study found that the combination of irinotecan with weekly cisplatin and etoposide shows promising antitumor activity in patients with stage IV small-cell and non-small-cell lung cancer.
Supporting Evidence
- The response rate for small-cell lung cancer was 91%, indicating high efficacy.
- The median survival time for small-cell lung cancer patients was 11.9 months.
- The study established a recommended dose of irinotecan for future trials.
Takeaway
This study tested a new combination of cancer drugs to see if they work better together. It looks like they do help some patients with lung cancer.
Methodology
Patients with metastatic lung cancer were treated with a combination of cisplatin, etoposide, and irinotecan, and their responses were evaluated.
Potential Biases
Potential biases may arise from the study design and patient selection criteria.
Limitations
The study had a small number of patients with small-cell lung cancer, which limits the evaluation of survival outcomes.
Participant Demographics
{"gender":{"male":41,"female":15},"age":{"median":58,"range":"38-70"},"performance_status":{"0":12,"1":44},"histology":{"small_cell_carcinoma":11,"adenocarcinoma":35,"squamous_cell_carcinoma":5,"large_cell_carcinoma":4,"others":1}}
Statistical Information
Confidence Interval
{"response_rate_sclc":"91% (59–100%)","response_rate_nslc":"38% (24–54%)","median_survival_sclc":"11.9 (9.7–15.6) months","median_survival_nslc":"10.1 (7.8–12.3) months"}
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website